Research programme: erythropoietin mimetics - BioRexis

Drug Profile

Research programme: erythropoietin mimetics - BioRexis

Alternative Names: EPO mimetic - BioRexis; EPO peptide mimetic - BioRexis; EPO receptor agonist peptide; Erythropoietin mimetics - BioRexis

Latest Information Update: 21 May 2007

Price : $50

At a glance

  • Originator BioRexis Pharmaceutical Corporation
  • Class
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anaemia

Most Recent Events

  • 21 Apr 2007 No development reported - Preclinical for Anaemia in USA (unspecified route)
  • 14 Jul 2004 Preclinical trials in Anaemia in USA (unspecified route)
  • 14 Jul 2004 The programme is available for licensing (http://www.biorexis.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top